Type 1 Diabetes

Catch up on major trial results, groundbreaking FDA decisions, and key clinician insights from major endocrinology conferences.

Leiter discusses the importance of earlier and more dramatic lipid-lowering interventions in patients with diabetes at risk of cardiovascular disease.

At ENDO 2026, findings suggest SBP reductions in adults with diabetes are driven by weight loss, not GLP-1 therapy type.

Alan Hutchison, MD, PhD, and Mishal Ali discuss the substantially increased risk of long-term mortality caused by diabetes in patients undergoing major organ transplants.

MiniMed 780G improved HbA1c and time in range in real-world diabetes data presented at ENDO 2026, with minimal hypoglycemia risk.

Teplizumab becomes the first disease-modifying therapy approved for patients recently diagnosed with stage 3 type 1 diabetes.

Catch up on any data and key clinician perspectives presented at the American Diabetes Association Scientific Sessions 2026.

DKA remains a growing challenge in diabetes care, with new data highlighting missed diagnoses, rising admissions, and higher costs.

A new substudy of VESALIUS-CV presented at ADA 2026 has confirmed that evolocumab’s cardioprotective effects extend to patients at risk from diabetes.

Viral Shah, MD, outlines the case for earlier ketone detection across diabetes types, the limitations of urine testing, and what CKM technology may change in clinical practice.

Sood discusses emerging diabetes technologies, from automated insulin delivery to dual glucose-ketone monitoring, at ADA 2026.

Teplizumab, which has recently seen a substantial label expansion into pediatric patients, is matching its safety and efficacy data in the clinic.

Catch up on major trial results, key FDA decisions, and more.

View the top 6 trials to watch ahead of a star-studded ADA 2026.

Jamie Wood, MD, discusses the impact of Afrezza’s recent FDA approval for pediatric patients with type 1 and type 2 diabetes.

The FDA has approved fast-acting inhaled insulin Afrezza for pediatric patients aged 6-18 years with T1D or T2D.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover the recent approval of the Libre Duo and Libre Duo 10 Day monitors.

The FDA accepted Bayer’s sNDA for finerenone in adults with type 1 diabetes and CKD based on albuminuria data from FINE-ONE.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the presentations that they’re looking forward to at ADA 2026.

This episode covers key trial results and presentations to keep an eye on as ADA 2026 approaches.

Schatz highlights the current limitations to a broader integration of T1D screening and suggests methods to circumvent these blockages.

The FDA has cleared the EndoTool IV Cloud for hospital IV insulin dosing support, expanding Glooko’s inpatient platform via the 510(k) pathway.

This episode covers recent advancements in treating type 1 diabetes, including the Tandem AID system for pregnant women and teplizumab for adolescents.

Catch up on key clinician insights, major FDA decisions, groundbreaking trial results, and more.

Catch up on any data and perspectives presented at the American Association of Clinical Endocrinology Annual Meeting 2026.